Kybella is a non-surgical solution for reducing submental fat (double chin), contouring and defining the jawline
However, this approach has remained unfeasible thus far
Ultimately, the success of the GLP-1 Bridge will depend on its ability to balance access, cost, and long-term value
Worth reading the coverage from STAT News: To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease
Inhibition of ferroptosis attenuates tissue damage and improves long-term outcomes after traumatic brain injury in mice
D'arino A, Caputo S, Bellei B
